Sherif Bayoumy, Inge M W Verberk, Lisa Vermunt, Eline Willemse, Ben den Dulk, Ans T van der Ploeg, Dasja Pajkrt, Elisa Nitz, Johanna M P van den Hout, Julie van der Post, Nicole I Wolf, Shanice Beerepoot, Ewout J N Groen, Victoria Tüngler, Charlotte E Teunissen
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, characterized by progressive neuromuscular degeneration resulting from mutations in the survival motor neuron ( SMN1 ) gene. The availability of disease-modifying therapies for SMA therapies highlights the pressing need for easily accessible and cost-effective blood biomarkers to monitor treatment response and for better disease management. Additionally, the wide implementation of newborn genetic screening programs in Western countries enables presymptomatic diagnosis of SMA and immediate treatment administration...
January 15, 2024: Clinical Chemistry and Laboratory Medicine: CCLM